SLC5A2 and heart failure: More recently, SGLT2 inhibitors have been recommended for the management of heart failure with mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF) (class IIA), according to the 2022 AHA/ACC/HFSA Heart Failure Management Guidelines.